An Early Phase II, Multicenter, Placebo-Controlled, Randomized, Double-Blind, Parallel-Group, Comparison Study to Investigate the Chemotherapy-Induced Peripheral Neuropathy (CIPN) Onset-Suppressing Effect and Safety of ONO-2910 in Patients With Breast Cancer Receiving Weekly Paclitaxel
Latest Information Update: 08 Apr 2025
At a glance
- Drugs ONO-2910 (Primary)
- Indications Chemotherapy-induced damage; Peripheral neuropathies
- Focus Adverse reactions; Therapeutic Use
- Sponsors Ono Pharmaceutical
Most Recent Events
- 31 Mar 2025 Status changed from active, no longer recruiting to completed.
- 07 Aug 2024 New trial record